ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor ...
Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) today announced the successful completion of the second dose cohort (single dose of 30 mg administered orally) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results